BioXcel Files for Chapter 11 as Teva Offers $57.5 Million Stalking-Horse Bid for Igalmi
BioXcel seeks Chapter 11 with a $19M DIP loan as Teva offers $57.5M plus milestones for Igalmi. Auction still open; sale not closed.
/ 2 items
BioXcel seeks Chapter 11 with a $19M DIP loan as Teva offers $57.5M plus milestones for Igalmi. Auction still open; sale not closed.
BioXcel Therapeutics announces positive Phase 2 results for BXCL501 in treating opioid withdrawal, showing better efficacy and tolerability than lofexidine amid the opioid crisis.